ARCA biopharma announced the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for AB201 (rNAPc2) as a potential treatment for patients hospitalized with COVID-19. Read more…
Eli Lilly and Company announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim data on combination therapy in recently diagnosed patients with mild-to-moderate COVID-19 – and plans to make these therapies broadly available to patients. Read more…
The Native Antigen Company has announced the introduction of ten new monoclonal antibodies recognizing SARS-CoV-2, the causative agent of COVID-19. Read more…
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
RedHill Biopharma announced the U.S. Phase 2 study with opaganib (Yeliva®, ABC294640) in patients hospitalized with severe COVID-19 pneumonia has passed its second pre-scheduled safety review by the independent Safety Monitoring Committee (SMC) with a unanimous recommendation to continue the study without change. Read more…
In a continuing effort to provide the facts about ID NOW to support public health interests, Abbott is sharing new interim clinical data results on its ID NOW COVID-19 rapid test. Read more…